Last reviewed · How we verify
B: CBDCA and Radiotherapy
CBDCA (carboplatin) is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, used in combination with radiotherapy to enhance tumor control.
CBDCA (carboplatin) is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, used in combination with radiotherapy to enhance tumor control. Used for Solid tumors treated with concurrent chemoradiotherapy (specific tumor type dependent on trial protocol).
At a glance
| Generic name | B: CBDCA and Radiotherapy |
|---|---|
| Sponsor | Japan Clinical Oncology Group |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA (forms crosslinks) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a second-generation platinum compound that binds to DNA and forms interstrand crosslinks, preventing DNA replication and transcription in cancer cells. When combined with radiotherapy, it acts as a radiosensitizer, enhancing the cytotoxic effects of radiation therapy. This combination approach is designed to improve local tumor control and overall treatment efficacy in solid tumors.
Approved indications
- Solid tumors treated with concurrent chemoradiotherapy (specific tumor type dependent on trial protocol)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Radiation-related toxicity (mucositis, dermatitis)
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
- Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (PHASE2, PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (PHASE1)
- Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |